SPY764.38+0.23%QQQ744.10+0.59%BTC/USD83,423.53−0.16%DIA507.66−0.18%GLD381.56+0.19%TLT77.18−0.37%
Benzinga

Geoff Meacham

Geoff Meacham is a managing director and senior healthcare analyst at Bank of America, where he focuses on biotechnology and pharmaceutical companies. He provides research, market analysis, and investment insights for institutional clients, covering trends in drug development, regulatory changes, and healthcare market dynamics. Meacham is recognized for his expertise in evaluating biotech pipelines and pharmaceutical industry performance.

Eli Lilly's Upcoming Obesity Drugs Highlight Bright Future, Says Optimistic Analyst
Eli Lilly's Upcoming Obesity Drugs Highlight Bright Future, Says Optimistic Analyst
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal

Geoff Meacham Recent News

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.
Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals
Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals
Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ: INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities.
BofA Downgrades CureVac On Limited 2022 Prospects
BofA Downgrades CureVac On Limited 2022 Prospects
There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst: Geoff Meacham upgraded Pfizer, Inc. (NYSE: PFE) shares from Neutral to Buy and increased the price target from $59 to $70.
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
Pfizer, Inc. (NYSE: PFE) announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S.
3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat
3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat
Johnson & Johnson (NYSE: JNJ) shares are higher Tuesday following the release of its third-quarter results.
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst
Merck & Co., Inc.
Moderna Analysts Debate Need For Biopharma's COVID-19 Booster Shot
Moderna Analysts Debate Need For Biopharma's COVID-19 Booster Shot
Moderna, Inc.
Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA
Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc.
Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish
Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish
A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc.
These 3 New Biotechs Have Differentiated Platforms, Technology: BofA
These 3 New Biotechs Have Differentiated Platforms, Technology: BofA
Following the expiry of IPO quiet periods for the recently listed Ambrx Biopharma Inc. (NASDAQ: AMAM), Cyteir Therapeutics, Inc. (NASDAQ: CYT) and Century Therapeutics, Inc.
Should Investors Be Worried About The Delta Strain Of COVID-19?
Should Investors Be Worried About The Delta Strain Of COVID-19?
The SPDR S&P 500 ETF Trust (NYSE: SPY) is up another 13% so far in the first half of 2021 as investors anticipate a full economic reopening this summer following the COVID-19 pandemic.
Why BofA Is Bearish On Moderna Despite COVID-19 Vaccine Success
Why BofA Is Bearish On Moderna Despite COVID-19 Vaccine Success
Moderna, Inc.
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over
Why This Pfizer Analyst Is Sidelined After Beat-And-Raise Q1
Why This Pfizer Analyst Is Sidelined After Beat-And-Raise Q1
Pfizer Inc.
Moderna Analyst: Unrealistic COVID-19 Vaccine Expectations Create Unfavorable Setup
Moderna Analyst: Unrealistic COVID-19 Vaccine Expectations Create Unfavorable Setup
Coronavirus vaccine developer Moderna Inc's (NASDAQ: MRNA) stock was moving lower Monday after a downgrade from BofA Securities.  The Moderna Analyst: Geoff Meacham downgraded Moderna shares from Neutral to Underperform and maintained a $150 price target.
Moderna Analyst Questions Whether COVID-19 Opportunity Can Support Valuation
Moderna Analyst Questions Whether COVID-19 Opportunity Can Support Valuation
Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine program is proceeding smoothly, with emergency use autho
Pfizer Analyst: Coronavirus Vaccine Moving Closer To Emergency Use Authorization
Pfizer Analyst: Coronavirus Vaccine Moving Closer To Emergency Use Authorization
Although the details of interim data from the Phase 3 trials of Pfizer Inc’s (NYSE: PFE) COVID-19 vaccine study rea unclear, the results represent “a solid win” for the company, according to BofA Securities.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved